Drug Approval | November 10, 2025
Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Subscribe To Our Newsletter & Stay Updated
